Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 11 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Phase I/ II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				D0810C00011 NCT00707707


2.		Dose-Finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				D0810C00012 NCT00628251


3.		Phase II Study of AZD2281 in Known BRCA or Recurrent High Grade Ovarian Cancer or Known BRCA/ Triple Neg Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Pharmaceutical / Industry				D0810C00020 NCT00679783

First Published: 9/20/2007


4.		Phase I Study of AZD2281 and Irinotecan Hydrochloride in Patients With Locally Advanced or Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 to 70				Other				CAN-NCIC-IND187 IND187, IND187, NCT00535353


5.		Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				D0810C00005 KU36-29, NCT00515866


6.		Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				KU36-93 D0810C00006, NCT00516438


7.		Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				KU36-96 D0810C00004, NCT00516724


8.		Open Label, Dose Escalation Phase I Study of AZD2281

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				20 to 74				Pharmaceutical / Industry				D0810C00001 NCT00572364

Last Modified: 8/27/2008 First Published: 3/27/2008


9.		Phase I Study of AZD2281 and Carboplatin in Patients With BRCA1/BRCA2-Associated or Familial Metastatic or Unresectable Breast and/or Ovarian Epithelial Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				NCI-08-C-0092 08-C-0092, NCI-P07253, NCT00647062

Last Modified: 9/15/2008 First Published: 5/12/2008


10.		Phase I Study of PARP Inhibitor AZD2281 in Combination With Cisplatin and Gemcitabine Hydrochloride in Patients With Unresectable or Metastatic Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				NCI-08-C-0128 08-C-0128, P07286, NCT00678132

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute